Arndt Vogel
@ArndtVogelClinician-scientist, ESMO ambassador, focussed on Liver cancer & precision oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪
Similar User
@KlempnerSam
@DrAngelaLamarca
@OncoAlert
@YJanjigianMD
@EileenMOReilly
@MPishvaian
@OncBrothers
@GABOUALFA
@FlorianLordick
@A_DAlessioMD
@AndresC27622123
@pashtoonkasi
@DrChoueiri
@KoheiShitara
@MyriamChalabi
ctDNA-based MRD & survival in resectable CRC @NatureMedicine doi.org/10.1038/s41591… 🔎CIRCULATE-🇯🇵 GALAXY, 2,240 pts 👉shorter DFS in MRD+ patients 👉Better outcome after sustained ctDNA clearance in response to ACT 🧐What else do we need to implement into clinical practice?…
Neoadjuvant nivolumab & relatlimab in locally advanced MSI CRC @NatureMedicine doi.org/10.1038/s41591… 🔎NICHE-3 phs 2 👉PR 97%, MPR 92%, pCR 68% 👉only one recurrence 👉Gr 3–4 irAEs 10% 💪Impressive, we need to find the most effective, least toxic combination @myESMO
Molecular profiling of mBRAFV600E mCRC @NatureMedicine doi.org/10.1038/s41591… 🔎BEACON phs-3 👉No impact of CMS, BM subtypes, GA (incl. RNF43), MSI or TMB on efficacy 👉more benefit w/ MEKi in immune-activated tumors? 👉interesting analysis on acquired resistance mutations…
ctDNA status & dynamics predict recurrence in resected extrahepatic cholangiocarcinoma @JHepatology doi.org/10.1016/j.jhep… 🔎STAMP 👉ctDNA+ after resection is predictive (as expected) 👉adj. CTx may convert some pts to ctDNA- w/ better outome (reassuring..) @myESMO @EASLnews…
Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory MSS mCRC @OncologyAdvance doi.org/10.1016/j.ejca… 🔎phs-1, 39 pts 👉ORR 36%, mPFS 5 & mOS 27.5 mo 👉3-yr PFS rate 19.3 % 🧐some long-term responders, 3 w/ potential cure, we need a biomarker...…
CAR T Cells & T-Cell Therapies for Cancer @JAMA_current doi.org/10.1001/jama.2… 🔎Translational Science Review 👉 6 CAR T-cells approved by FDA in hematology, none in solid cancers, TILs in melanoma 👉Cave cytokine release syndrome & neurotoxicity 🧐certainly more to come...…
Risk Score for HCC in pts Without Viral Hepatitis or Cirrhosis @JAMANetworkOpen doi.org/10.1001/jamane… ❓Can we identify pts WITHOUT viral hep & cirrhosis at risk 👉you need: age, sex, race/ ethnicity, BMI, DM, 🚬,🍷 & Fib-4 🧐Important, since MASLD & ALD are on the rise…
Psoriasis Risk With Immune Checkpoint Inhibitors @JAMADerm doi.org/10.1001/jamade… ❓What is the risk to develop psoriasis with ICI 🔎135 230 pts 👉2-fold increased, 0.5 vs 0.2% 🧐Uncommon, but be aware & provide optimal care @myESMO
Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma @JAMASurgery doi.org/10.1001/jamasu… 🔎98 pts symptomatic follow-up, 235 pts routine imaging 👉mOS 23 vs 28 mo 👉more recurrence-focused treatment & longer OS w/ imaging @myESMO
Trastuzumab Deruxtecan in Advanced Solid Tumors With HER 2 Amplification Identified by cfDNA @JCO_ASCO doi.org/10.1200/JCO.23… 🔎HERALD/EPOC1806 phs II Basket, 61 pts, 16 tumor types 👉 ORR 56%, PFS 7.0 mo, DoR 8.8 mo, mOS 14.6 mo 🧐cfDNA useful to identify HER2 amplified tumors…
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma @JCO_ASCO doi.org/10.1200/JCO.24… 🔎EXTEND phs II, 41 pts, ≤five mets 👉PFS 10.3 vs 2.5 mo 🧐local intervention plus CTx in oligometastic #PDAC promising, but no OS…
🔥off the press - our 🇪🇺RWD study: Atezolizumab/bevacizumab and lenvatinib for HCC @HepCommJournal doi.org/10.1097/HC9.00… 👉Similar OS for Lenva vs AB 👉Risk of hepatic decompensation for pts w/ impaired liver function under AB 🧐More data for clinical decision making @myESMO…
Immunotherapy response induces divergent tertiary lymphoid structures in HCC @NatImmunol doi.org/10.1038/s41590… 👉 intratumoral TLS density⬆️after ICB -> MPR & RFS ⬆️ 👉CD20+CXCL13+ LAs surrogate for TLS ? 👉involuted TLS morphology after tumor regression 🥲exciting times for…
Risk of HCC in Subcentimeter Liver Nodules Identified on Surveillance Ultrasound @AGA_CGH doi.org/10.1016/j.cgh.… 🔎 Systematic Review, 9 studies, 888 pts 👉risk of HCC: 21.3% 👉risk factors: older age, male sex, elevated AFP, low plts, CP B 🧐repeat ultrasound in 3-6 mo…
Liver Cancer in 2021: Global Burden of Disease Study @JHepatology doi.org/10.1016/j.jhep… 👉2021: 529.202 cases & 483.875 👉25% increased in deaths since 2010 👉HBV- & HCV-HCC⬇️, alcohol stable, MASLD⬆️ @myESMO @EASLnews @ILCAnews #livertwitter
Devimistat (CPI-613) with mFOLFOXIRI vs FFX for metastatic #PDAC @JCO_ASCO doi.org/10.1200/JCO.23… 🔎Phs-3 AVENGER 500 Study, 528 pts 👉Interesting MOA -> 🎯mitochondrial respiration by inhibiting PDH and aKGDH 🧐Unfortunately ⛔️, but supports FFX as backbone for future trials…
Safety & efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis Cancer Treatment Reviews doi.org/10.1016/j.ctrv… 👉ADC & ICI are very promising and on the rise in multiple tumour types 👏Great summary & overview @myESMO
Prevalence of Chronic liver disease in Cholangiocarcinoma: a Meta-Analysis @AGA_CGH doi.org/10.1016/j.cgh.… 👉118.068 pts, 109 studies 👉Overall prevalence: 25.23%, 10% w/ cirrhosis 👉HBV 8% 👉HCV 4% 👉ALD 4% 👉MASLD 5% 👉PBC 1% 👉PSC 8% @myESMO @EASLedu @ILCAnews #livertwitter
United States Trends
- 1. Mike 1,84 Mn posts
- 2. Serrano 239 B posts
- 3. #NetflixFight 72,1 B posts
- 4. Canelo 16,5 B posts
- 5. Father Time 10,7 B posts
- 6. #netflixcrash 15,8 B posts
- 7. Logan 78,6 B posts
- 8. He's 58 25,7 B posts
- 9. Rosie Perez 14,9 B posts
- 10. ROBBED 101 B posts
- 11. Boxing 299 B posts
- 12. #buffering 10,9 B posts
- 13. Shaq 16,1 B posts
- 14. My Netflix 83,1 B posts
- 15. Roy Jones 7.168 posts
- 16. Tori Kelly 5.240 posts
- 17. Cedric 21,9 B posts
- 18. Ramos 69,8 B posts
- 19. Barrios 50,5 B posts
- 20. Muhammad Ali 18,3 B posts
Who to follow
-
Sam Klempner
@KlempnerSam -
Angela Lamarca
@DrAngelaLamarca -
OncoAlert
@OncoAlert -
Yelena Y. Janjigian MD
@YJanjigianMD -
Eileen M O’Reilly
@EileenMOReilly -
Mike Pishvaian
@MPishvaian -
Oncology Brothers
@OncBrothers -
Ghassan Abou-Alfa
@GABOUALFA -
Florian Lordick
@FlorianLordick -
Antonio D'Alessio
@A_DAlessioMD -
Andres Cervantes
@AndresC27622123 -
Pashtoon Kasi MD, MS
@pashtoonkasi -
Toni Choueiri, MD
@DrChoueiri -
Kohei shitara
@KoheiShitara -
Myriam Chalabi
@MyriamChalabi
Something went wrong.
Something went wrong.